本文转载自药视声作者:安森2025年7月29日,默沙东发布二季度战略调整报告,宣布终止与康方生物合作的CTLA-4单抗MK-1308在非小细胞肺癌领域的开发。这一动作与诺华、辉瑞等跨国药企自2023年启动的战略调整形成呼应——通过优化管线布局应对专利悬崖。数据显示,2023年全球TOP10药企管线削减幅度达18%,但同期研发投入强度同比增加2.3%,表明行业正从规模扩张转向价值导向的创新竞争。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.